Evidence map›Paper›PMID 16036794›Full record

ArticleJournal of neurovirology2005

Retinoid-induced mu opioid receptor expression by phytohemagglutinin-stimulated U937 cells.

Walter Royal, Michelle V Leander, Reid Bissonnette

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurovirology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Opioid receptors and signaling on cells from the immune system.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2006
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Walter RoyalNeuroscience Institute, Morehouse School of Medicine, Atlanta, Georgia 30310-1495, USA. wroyal@msm.edu
Michelle V Leander
Reid Bissonnette
Morehouse School of Medicine · USLigand Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opioid use may be associated with an increased risk of neurological disease in human immunodeficiency virus (HIV) infection through effects on immune cell function. Studies were performed to examine the effects of specific retinoid receptor activation on mu opioid receptor (MOR) production by phytohemagglutinin (PHA)-stimulated U937 cells, a mononuclear cell line. PHA stimulation increased activation of the MOR promoter as well as levels of MOR mRNA, total receptor protein in cell lysates, and surface and cytoplasmic receptor expression. Retinoid X receptor (RXR) agonist and retinoic acid receptor (RAR) antagonist further increased MOR expression by the PHA-stimulated cells. In contrast, MOR expression was suppressed by RAR agonist and by RXR antagonist. Finally, opioid receptor binding was also increased by RXR agonist and RXR antagonist; no increase in binding occurred in the presence of RAR agonists and RXR antagonist. All together, these studies suggest that MOR expression in U937 cells can be differentially regulated by specific retinoid receptor activation. Such effects may have important clinical relevance for opioid users with HIV infection, including individuals with neurological disease.

Indexed as

Cell DifferentiationGene Expression RegulationHumansPhytohemagglutininsPolymerase Chain ReactionPromoter Regions, GeneticReceptors, Opioid, muReceptors, Retinoic AcidRetinoid X ReceptorsRNA, MessengerSignal TransductionU937 CellsPhytohemagglutininsReceptors, Opioid, muReceptors, Retinoic AcidRetinoid X ReceptorsRNA, Messenger

Identifiers

PMID16036794
OpenAlexW2028859389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.